The current widely accepted molecular tool for AD diagnosis is based on monitoring of the gold standard biomarker triplet, Aβ1-42, total-tau, and p-tau 181 in the cerebrospinal fluid (CSF) [9,10,11]. This evidence concerns the gene MAPT and Alzheimer disease.